Inclusion Criteria:

          1. Subjects must have histologic confirmation of advanced, biopsy-accessible, measurable
             cancers of the following histologies:

               -  Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or
                  HPV-associated HNSCC after failure of prior therapy

               -  Locally recurrent or metastatic breast cancer

               -  Sarcoma

               -  Merkel Cell Carcinoma (MCC)

               -  Cutaneous T cell Lymphoma (CTCL)

               -  Melanoma after failure of available therapies

               -  GU cancers with accessible metastases (e.g., bladder, renal)

               -  Any solid tumors with masses that are accessible

          2. Subjects with measurable disease, must have at least 2 lesions (1 measurable lesion
             and 1 biopsy/injectable lesion, which will not need to be measurable).

          3. Any number of prior systemic therapies.

          4. ECOG performance status 0-1.

          5. Laboratory parameters for vital functions should be in the normal range or not
             clinically significant.

        Exclusion Criteria:

          1. Prior treatment with combination CTLA-4 and PD-1/PD-L1 blockade, with the exception of
             subjects with melanoma.

          2. Participants may not have been treated intratumorally with polyICLC.

          3. Subjects with history or evidence upon physical examination of central nervous system
             (CNS) disease, including primary brain tumor, seizures not controlled with standard
             medical therapy, any active brain metastases, or, within 6 months of the first date of
             treatment on this study, history of cerebrovascular accident (CVA, stroke), transient
             ischemic attack (TIA) or subarachnoid hemorrhage.

          4. Active, suspected or prior documented autoimmune disease, clinically significant
             cardiovascular disease or clinically uncontrolled hypertension.

          5. History of pneumonitis or interstitial lung disease or any unresolved immune-related
             adverse events following prior biological therapy.

          6. Other malignancy within 2 years prior to entry into the study, except for those
             treated with surgical therapy only (e.g., localized low-grade cervical or prostate
             cancers).

          7. Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who
             require drainage gastrostomy tube and/or parenteral hydration or nutrition.

          8. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to
             Hepatitis B or C without evidence of active infection may be allowed.

          9. History of severe allergic reactions to any unknown allergens or any components of the
             study drugs.

         10. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding
             disorders).

         11. History of allogeneic organ transplant.